These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 2516611

  • 1. Plasma oxalate concentration, oxalate clearance and cardiac function in patients receiving haemodialysis.
    Tomson CR, Channon SM, Ward MK, Laker MF.
    Nephrol Dial Transplant; 1989; 4(9):792-9. PubMed ID: 2516611
    [Abstract] [Full Text] [Related]

  • 2. Plasma oxalate in patients receiving continuous ambulatory peritoneal dialysis.
    Tomson CR, Channon SM, Parkinson IS, Owen JP, Ward MK, Simpson JM, Laker MF.
    Nephrol Dial Transplant; 1988; 3(3):295-9. PubMed ID: 3140104
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Oxalate clearance by haemodialysis--a comparison of seven dialysers.
    Franssen CF.
    Nephrol Dial Transplant; 2005 Sep; 20(9):1916-21. PubMed ID: 15998647
    [Abstract] [Full Text] [Related]

  • 6. Plasma concentration and peritoneal clearance of oxalate in patients on continuous ambulatory peritoneal dialysis (CAPD).
    Yamauchi A, Fujii M, Shirai D, Mikami H, Okada A, Imai E, Ando A, Orita Y, Kamada T.
    Clin Nephrol; 1986 Apr; 25(4):181-5. PubMed ID: 3698351
    [Abstract] [Full Text] [Related]

  • 7. Plasma oxalate following kidney transplantation in patients without primary hyperoxaluria.
    Elgstoen KB, Johnsen LF, Woldseth B, Morkrid L, Hartmann A.
    Nephrol Dial Transplant; 2010 Jul; 25(7):2341-5. PubMed ID: 20167571
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Oxalate dynamics and removal rates during haemodialysis and peritoneal dialysis in patients with primary hyperoxaluria and severe renal failure.
    Watts RW, Veall N, Purkiss P.
    Clin Sci (Lond); 1984 May; 66(5):591-7. PubMed ID: 6368103
    [Abstract] [Full Text] [Related]

  • 12. [Diurnal variation in plasma oxalate concentration and oxalate clearance in calcium oxalate stone formers with special reference to the effect of oxalate loading].
    Kinoshita N.
    Hinyokika Kiyo; 1987 Sep; 33(9):1331-41. PubMed ID: 3434488
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis.
    Hoppe B, von Unruh GE, Blank G, Rietschel E, Sidhu H, Laube N, Hesse A.
    Am J Kidney Dis; 2005 Sep; 46(3):440-5. PubMed ID: 16129205
    [Abstract] [Full Text] [Related]

  • 20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.